

Precision Human Biosciences Awarded National Science Foundation Grant

San Diego, CA October 14, 2007 –Precision Human Biosciences (PHB), a neurodiagnostic company developing a first in class, proprietary blood test for Major Depressive Disorder, has been awarded a National Science Foundation grant to further the development of its proprietary technology platforms.

“We are pleased to announce the National Science Foundation’s recognition of Ridge’s technological accomplishments. This prestigious grant will enable us to further our work toward a marketable product,” stated Larry G. Stambaugh, Chairman of Ridge.

This project, under the direction of Dr. John Bilello, Chief Scientific Officer, is entitled “ SBIR: Phase I: Molecular Interaction Measurement System: A label-free Detection Platform”.

The Company, founded in 2006, is developing diagnostic assays using biological markers for diagnosing and monitoring treatment of neuropsychiatric diseases.

Precision Human Biosciences (PHB)

PHB is a neurodiagnostic company commercializing a breakthrough first-in-class, proprietary blood test for the diagnosis and treatment monitoring of Major Depressive Disorder (MDD). Products are based on a proprietary Human Biomarker Library and Hyper-Mapping™ technology. PHB intends to develop a comprehensive neuropsychiatric disease diagnostic franchise. PHB testing services will be provided through a CLIA certified laboratory in North Carolina, then through diagnostic test kits sold worldwide. The Company is located in San Diego, CA and Research Triangle Park, NC.